In this white paper, Lonza's Michiya Hayakawa, provides an overview of the current market environment and presents strategies for manufacturing highly potent active drugs, for which demand is increasing. Also provided, are key points for promoting projects that utilize special formulation technologies.
You may also be interested in:
Drug Substance (API/HPAPI)
Regulatory Services
API Services
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center
smart capsule image
White paper
State-Of-The-Art And Future Perspectives In Ingestible Remotely Controlled Smart Capsules For Drug...
From sensing to imaging, and sampling to delivery, smart capsules have a key role to play in...
Article
Simplify the manufacturing process, improve scalability and offer new opportunities for oral...
Pharmaceutical formulators often face considerable challenges in maintaining the stability and...
Aanchal Tomar profile
Interview
Strengthening our presence within APAC through increased penetration is a key focus
Aanchal Tomar Executive Director, Asia Pacific, Lonza CHI interview where she speaks about Lonza...
UC-II Active Lifestyles eBook
Infographic
UC-II® undernatured type II collagen: key trends in the evolving active lifestyle market
Explore the future of the joint health market, and keep consumers of all ages moving the way they...
product hero image
White paper
Exploring the Need for Dose-Flexible Manufacturing
Bringing a new drug to market is a complex journey, often involving various dosage forms throughout...
Center of Applied Sustainability
Article
Lonza CHI’s Center of Applied Sustainability
Building momemtum_QA_DEC24
Article
Expert Q&A: Partnering for Success in the Supplement Market
Explore how Lonza's innovative platform and visionary approach to partnership empowers brands with a...
AI-Enabled Route Scouting Service Scientists
Webinar (on-demand)
Innovative AI-Driven Solutions to Address the Growing Complexity of APIs
Developing innovative medicines often involves intricate small-molecule APIs with lengthy synthetic...
Webinar (on-demand)
Charting a Successful CMC Journey for Your ADC Drug Product
Bioconjugates and Antibody drug conjugates (ADCs) are revolutionizing cancer therapy with their...
ADC vial with gradient background - close crop
Interview
Expert Q&A: Accelerate Your ADC Journey
Filling the Need for Integrated Bioconjugate Solutions Antibody drug conjugates (ADCs) are...
KC Video thumbnail
Video
mRNA and LNP Encapsulation Capabilities at our Geleen/NL Center of Excellence
Discover how our team, with its impressive mRNA/LNP track record, can help you progress your...
Mammalian Biologics Drug Substance Manufacture MC1
Article
How Emerging Biotechs can Benefit by Partnering with a CDMO for Early Stage Development
The partnership between CDMOs and emerging biotech companies in early-stage development can be...